Drug firm Zydus Cadila has received final approval from the US health regulator to market doxycycline tablets, used for treatment of different types of bacterial infections such as acne and eye infection.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 50 mg, 75 mg, 100 mg and 150 mg, Zydus Cadila said in a BSE filing today.
The company will manufacture the drug at the group's formulations facility at the pharma SEZ in Ahmedabad.
It has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
The stock of the company's listed entity Cadila Healthcare was up 1.89 per cent at Rs 476 on the BSE today.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)